Non-Small Cell Lung Cancer research hub
50 indexed studies · 22 currently recruiting
- active not recruitingPHASE1
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
This study looks at a new drug, ABBV-400, for advanced cancers like lung and bowel cancer. We're checking how safe it is and if it helps shrink tumours, both on its own and with another drug.
United States · Australia · France - active not recruitingPHASE2
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
This study compares two treatments for a type of lung cancer that hasn't been treated before. It looks at a new drug called tobemstomig with chemotherapy, against another drug called pembrolizumab with chemotherapy, to see which is safer and works better.
United States · Australia · Belgium - active not recruitingPHASE3
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
This study looks at a new way to treat a type of lung cancer that has grown despite earlier treatment. It combines standard chemotherapy with a drug called osimertinib, or with a dummy pill, to see which works better and is safer.
United States · China · Germany - active not recruitingPHASE3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
This study compares two medicines, X-396 (ensartinib) and crizotinib, for people with a specific type of lung cancer called ALK-positive non-small cell lung cancer. It looks at how well each medicine works and if they are safe.
United States · Argentina · Australia - active not recruitingNA
A Nutritional Supplement to Support People With Non-small Cell Lung Cancer
This study looks at how a nutritional supplement might help people with a type of lung cancer called non-small cell lung cancer. It aims to see if the supplement can improve how patients respond to their regular cancer treatments, like immunotherapy or chemotherapy.
Canada - active not recruitingPHASE1
SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial
This study looks at a special type of radiation (SBRT) for a specific lung cancer (Non-Small Cell Lung Cancer) that's near vital organs. We want to find the safest and most effective dose to treat these tumours, whilst carefully monitoring patients for any side effects.
Canada - active not recruitingPHASE1
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
This study is testing a new medicine, KIN-2787, alone or with another drug, binimetinib, for adults with certain advanced cancers. It aims to see how safe the drug is, if it works, and how the body handles it. It's for people whose cancer has specific genetic changes (BRAF/NRAS mutations).
United States · Australia · China - recruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
United States · Argentina · Australia - recruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
United States · Argentina · Australia - recruitingPHASE3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.
United States · Australia · Austria - recruitingNA
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
This study looks at lung cancer patients with specific gene changes (EGFR mutations) who have had surgery. Researchers want to understand why some cancers return after a targeted treatment called osimertinib and how to find the best future treatments if needed.
France - active not recruitingPHASE3
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
This study is for people with advanced non-small cell lung cancer that has a specific gene change (EGFR Exon20ins). It compares a new medicine called sunvozertinib with standard chemotherapy to see which works better and is safer as a first treatment.
United States · Argentina · Australia - active not recruitingPHASE2
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
This study looks at combining chemotherapy with two new drugs, tiragolumab and atezolizumab, before and after surgery for certain lung cancers. It aims to see if this combination is safe and effective for patients with non-small cell lung cancer.
Germany - active not recruitingPHASE1, PHASE2
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
This study is testing a new cancer medicine, BI-1910, alone and with another drug called pembrolizumab, for people with advanced solid tumours like lung cancer or liver cancer. It aims to find the right dose and check how safe and effective it is.
Denmark · Germany · Spain - recruitingPHASE1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
This study is testing a new drug, ASP5834, for adults with certain solid cancers. It aims to find the right dose and check for side effects, sometimes given with another cancer drug called panitumumab, especially for bowel cancer.
United States · France · Japan - recruitingPHASE4
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
This study looks at how well older people (70+) with specific lung cancer are treated with standard medicines. It collects real-world information about their health, treatments, safety, and how their quality of life is affected.
France - recruiting
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
This study looks at whether we can find signs of non-bowel cancers, like lung or pancreatic cancer, in a small sample of mucus taken from a person's bottom. We're testing a new, simple device to see if it can help detect these cancers earlier.
United Kingdom - active not recruitingPHASE3
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
This study looks at a new way to give a lung cancer medicine called pembrolizumab. It compares giving it through a drip in your arm (IV) versus a new injection under the skin (SC) for people with advanced non-small cell lung cancer. Researchers want to see how the injection works.
United States · China · Germany - recruitingPHASE1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
This study looks at a new drug, LY4050784, for advanced or metastatic solid cancers. We want to see if it's safe and effective, on its own or with other medicines, especially for cancers with a specific gene change called SMARCA4 (BRG1).
United States · France · Germany - active not recruitingPHASE1
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
This study combines two drugs, tepotinib and pembrolizumab, for advanced non-small cell lung cancer. It explores if tepotinib can make immunotherapy like pembrolizumab more effective, especially for cancers that usually don't respond well to such treatments.
United Kingdom - recruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
United States · Argentina · Australia - recruitingPHASE2
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
This study is testing a new drug, zanidatamab, for different cancers like lung, sarcoma, head and neck, bowel, and womb cancer. It's for people whose cancer has a specific change in the HER2 gene and hasn't responded to previous treatments.
France - active not recruitingPHASE1, PHASE2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This study looks at a new drug, selpercatinib, for advanced cancers, including certain lung, thyroid, and other solid tumours that have a specific genetic change called a RET alteration. Researchers want to check its safety, how it works in the body, and if it helps shrink tumours.
United States · Australia · Canada - recruitingPHASE1, PHASE2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
This study is testing a new drug, TUB-040, for ovarian cancer and a type of lung cancer (non-small cell lung cancer) when standard treatments haven't worked. It checks how safe it is, how it moves in the body, and if it helps shrink tumours. The study aims to find the best dose.
United States · Belgium · Germany - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
This study is looking at a new treatment called MYTX-011 for non-small cell lung cancer. It's an early-stage trial to see if the treatment is safe and how well it works in people. Researchers want to find out the best dose and understand its effects.
France · Spain - active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
This study looks at combining a drug called osimertinib with chemotherapy for a type of lung cancer. It wants to see if this combination works better than osimertinib alone for patients with a specific genetic change in their cancer, hoping to delay the cancer getting worse.
United States · Argentina · Australia - active not recruitingNA
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer
This study looks at adding special radiotherapy (SABR) to standard treatment for some lung cancer patients. It aims to see if combining these treatments improves outcomes like how long patients live and how well their cancer is controlled.
United Kingdom - recruitingNA
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
This study looks at why a lung cancer treatment, amivantamab, stops working for some patients with a specific type of lung cancer (NSCLC with EGFR exon 20 insertion). We collect blood and tissue samples to understand these reasons better.
France - active not recruitingPHASE2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new combinations of medicines for advanced lung cancer that has spread. It combines a drug called sacituzumab govitecan (SG) with pembrolizumab, and sometimes with chemotherapy agents like carboplatin or cisplatin, to see how well they work together.
United States · Australia · Canada - active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
United States · Argentina · Australia - active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
United States · Australia · Brazil - recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
United States · Argentina · Australia - recruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
United States · Argentina · Australia - active not recruitingPHASE1
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study is testing a new drug, PF-08046049/SGN-BB228, for advanced melanoma and other difficult-to-treat solid cancers. It aims to find a safe dose and see how well it works, as well as checking for side effects.
United States · Canada · France - active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, divarasib, for advanced lung cancer with a specific genetic change (KRAS G12C). It compares divarasib to existing treatments, sotorasib or adagrasib, to see how well they work and if they are safe.
United States · Argentina · Australia - recruitingPHASE1
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
This study is testing a new cancer medicine, OVM-200, for the first time in people. It involves up to 52 patients with prostate, lung, or ovarian cancer to check if it's safe and how well it works. It's given as an injection under the skin.
United Kingdom - recruitingPHASE2, PHASE3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
This study is testing a new drug called pumitamig, combined with usual chemotherapy and other drugs, for people with a type of lung cancer called non-small cell lung cancer. It aims to see if this new combination is safe and works well.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This study is testing a new combination of two medicines, Tuvusertib and Cemiplimab, for people with a specific type of lung cancer (non-squamous NSCLC). It's for those whose cancer has grown despite previous treatments, including immunotherapy and chemotherapy.
United States · Belgium · France - recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
This study looks at a new blood test to find cancer early in people who have already been treated for certain cancers. It aims to see if this test can tell when cancer might come back, helping doctors give the best care sooner.
United States · France · Germany - active not recruitingPHASE2
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat a type of lung cancer that can be removed by surgery. It combines standard chemotherapy with a new immunotherapy drug (durvalumab) and different types of radiation therapy to see if this mix works better.
Germany · Switzerland - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
United States · Argentina · Australia - recruitingPHASE1
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is testing a new medicine, DO-2, for people with advanced solid tumours, especially lung cancer, that have specific genetic changes and where other treatments haven't worked. It aims to see if DO-2 is safe and how it moves through the body.
Belgium · France · Netherlands - recruitingPHASE1, PHASE2
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing new combination medicines, BNT326 and BNT327, for people with advanced non-small cell lung cancer. It aims to find a safe dose and see how well they work, both for those who've had previous treatments and those who haven't.
United States · Australia · China - active not recruitingPHASE3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This study looks at a drug called osimertinib for people with a certain type of early-stage lung cancer after surgery. We want to see if it helps prevent the cancer from coming back compared to a dummy drug (placebo).
United States · Argentina · Brazil - recruitingPHASE4
Dabrafenib and/or Trametinib Rollover Study
This study allows patients already on dabrafenib and/or trametinib for certain cancers to continue treatment if their doctor thinks it's helping and they meet specific criteria. It's for people already in another study.
United States · Argentina · Austria - active not recruitingPHASE2
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
This study is for people with certain types of non-small cell lung cancer. It tests a new approach using a drug called durvalumab with chemotherapy, followed by either surgery or other treatments. The aim is to see how well it works and if it's safe.
United States · Austria · Canada - active not recruitingPHASE1
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study is testing a new cell therapy for certain cancers that have a specific protein. It aims to see if it's safe and how well people tolerate it. The therapy uses your own modified cells to fight the cancer. Some participants will also receive a small amount of radiation.
United States · Canada - active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
United States · Australia · Belgium